Sandoz Group AGSDZXF 18 Forward PE Ratio is 21.97 as of Jul. 11, 2026. GuruFocus rates SDZXF with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 409 Drug Manufacturers companies, Sandoz Group AG ranks worse than 59.17% on this metric.
Sandoz Group AG (OTCPK:SDZXF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Sandoz Group AG Forward PE Ratio Related Terms
Sandoz Group AG Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG Forward PE Ratio Chart
Sandoz Group AG Annual Data
Trend
2023-12
2024-12
2025-12
Forward PE Ratio
12.29
12.10
18.50
Sandoz Group AG Semi-Annual Data
2023-12
2024-06
2024-12
2025-06
2025-12
Forward PE Ratio
12.29
12.61
12.10
16.97
18.50
SDZXF vs ZTS, UTHR, VTRS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Sandoz Group AG (SDZXF) has a Forward PE Ratio of 21.97 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sandoz Group AG and its competitors. According to the industry distribution chart, Sandoz Group AG ranks #242 out of 409 companies in the Drug Manufacturers industry, placing it in the top 59.2%.
Is Sandoz Group AG's Forward PE Ratio too high?
Sandoz Group AG's current Forward PE Ratio is 21.97. The Drug Manufacturers industry median Forward PE Ratio is 17.36. Sandoz Group AG's value of 21.97 is 26.6% above this industry median. Based on the distribution chart, Sandoz Group AG ranks #242 out of 409 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #242 out of 409 companies for Forward PE Ratio. This places Sandoz Group AG in the lower half of its industry. The industry median Forward PE Ratio is 17.36. Sandoz Group AG's value of 21.97 is 26.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.36, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current Forward PE Ratio of 21.97 is 26.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Forward PE Ratio is 21.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (SDZXF) has a current Forward PE Ratio of 21.97. The current Forward PE Ratio is 21.97 and 26.6% above the Drug Manufacturers industry median of 17.36. Sandoz Group AG's overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Sandoz Group AG (SDZXF), the current Forward PE Ratio is 21.97 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
18GF Score
Get the complete analysis for SDZXF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDZXF has been successfully added to your 